Aetna Is Uncertain About Its ACA Participation
Just a week after a judge blocked Aetna’s proposed merger with Humana, the health insurer is unsure about future participation on the Affordable Care Act (ACA) exchanges. According to the AP, the company currently sells ACA coverage in 4 states, and it will decide whether or not to continue by April 1. Aetna’s chairman and CEO said the company isn’t considering entering new markets and that it only sees “bad news” in the future. April 1 is the deadline when health insurers have to decide if they will participate in the ACA exchanges the next year.
Teva Loses 4 Patents on MS Drug
A court has invalidated Teva Pharmaceutical Industries Ltd’s 4 patents on the multiple sclerosis drug Copaxone. The drug was Teva’s top seller and generated one-fifth of the company’s sales, but the ruling may open the door to generic competition, reported Bloomberg. This is the latest in a series of bad news for the drug maker, which recently cut its 2017 profit forecast and paid $519 million in a settlement admitting to paying bribes in some countries.
Hawaii Hopes to Save Some Parts of the ACA
Even as Republicans continue to debate the best way to replace the ACA, Hawaii is planning to save parts of the law. The state is introducing bills that would merge consumer protections under the ACA into state law. Included in the bills is guaranteed coverage for preexisting conditions and mandated benefits, such as pregnancy care. Hawaii is not alone in trying to preserve what it thinks are the best parts of the ACA. Other states are considering measures to add the ACA’s contraception mandate into state law.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More